Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 14 | 2025 | 3016 | 1.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 895 | 1.180 |
Why?
|
| Parents | 3 | 2022 | 1128 | 0.860 |
Why?
|
| Allopurinol | 4 | 2023 | 79 | 0.740 |
Why?
|
| Mercaptopurine | 4 | 2022 | 72 | 0.740 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 157 | 0.610 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 441 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 265 | 0.500 |
Why?
|
| Cephalosporins | 1 | 2017 | 135 | 0.490 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 707 | 0.460 |
Why?
|
| Medical Oncology | 4 | 2025 | 245 | 0.430 |
Why?
|
| Physicians | 1 | 2021 | 635 | 0.430 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2023 | 195 | 0.430 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 259 | 0.420 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 71 | 0.350 |
Why?
|
| Fertility Preservation | 2 | 2023 | 62 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2596 | 0.330 |
Why?
|
| Hospitalization | 7 | 2025 | 1950 | 0.320 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2022 | 15 | 0.320 |
Why?
|
| Adolescent | 23 | 2025 | 20987 | 0.300 |
Why?
|
| Antioxidants | 1 | 2012 | 331 | 0.300 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 315 | 0.290 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 317 | 0.280 |
Why?
|
| Child | 25 | 2025 | 26341 | 0.280 |
Why?
|
| Medulloblastoma | 1 | 2012 | 377 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2021 | 282 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1826 | 0.220 |
Why?
|
| Humans | 35 | 2025 | 131163 | 0.220 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2025 | 68 | 0.220 |
Why?
|
| Male | 21 | 2025 | 64957 | 0.210 |
Why?
|
| Mental Disorders | 1 | 2012 | 910 | 0.210 |
Why?
|
| Young Adult | 10 | 2025 | 10103 | 0.200 |
Why?
|
| Thioguanine | 2 | 2022 | 21 | 0.190 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 17 | 0.190 |
Why?
|
| Boston | 2 | 2021 | 117 | 0.180 |
Why?
|
| Shock | 1 | 2023 | 100 | 0.180 |
Why?
|
| Female | 20 | 2025 | 70963 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 4066 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1129 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2025 | 483 | 0.180 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 32 | 0.170 |
Why?
|
| Fever | 1 | 2024 | 312 | 0.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.170 |
Why?
|
| Down Syndrome | 1 | 2024 | 233 | 0.170 |
Why?
|
| Child, Preschool | 10 | 2025 | 15110 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3436 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2025 | 571 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 222 | 0.160 |
Why?
|
| Mycoses | 1 | 2021 | 110 | 0.160 |
Why?
|
| Maintenance Chemotherapy | 2 | 2023 | 22 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Cross Infection | 1 | 2022 | 339 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 22 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 69 | 0.140 |
Why?
|
| Hypoglycemia | 2 | 2018 | 190 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 614 | 0.140 |
Why?
|
| Communication | 1 | 2022 | 543 | 0.130 |
Why?
|
| Bacteremia | 1 | 2022 | 446 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 493 | 0.130 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 808 | 0.130 |
Why?
|
| Infant | 8 | 2025 | 13352 | 0.130 |
Why?
|
| Fever of Unknown Origin | 1 | 2017 | 44 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 514 | 0.130 |
Why?
|
| Neutropenia | 2 | 2018 | 209 | 0.120 |
Why?
|
| Quality of Life | 2 | 2023 | 2082 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 315 | 0.120 |
Why?
|
| Methotrexate | 2 | 2018 | 350 | 0.120 |
Why?
|
| Aftercare | 1 | 2017 | 157 | 0.110 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 159 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2022 | 800 | 0.110 |
Why?
|
| Registries | 1 | 2021 | 1634 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 395 | 0.100 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 13 | 0.100 |
Why?
|
| Survivors | 2 | 2017 | 344 | 0.100 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 34 | 0.100 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.100 |
Why?
|
| Biotransformation | 1 | 2013 | 54 | 0.100 |
Why?
|
| Drug Evaluation | 1 | 2013 | 101 | 0.100 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 43 | 0.100 |
Why?
|
| Methyltransferases | 1 | 2013 | 78 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1020 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 35 | 0.090 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 48 | 0.090 |
Why?
|
| Pediatrics | 1 | 2021 | 1252 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 512 | 0.090 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 148 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 172 | 0.090 |
Why?
|
| Adult | 7 | 2025 | 31282 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2001 | 895 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1336 | 0.080 |
Why?
|
| Risk Factors | 5 | 2025 | 11074 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 526 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2332 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 960 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2021 | 292 | 0.060 |
Why?
|
| Age Factors | 3 | 2024 | 2825 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 689 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2595 | 0.060 |
Why?
|
| Axilla | 1 | 2025 | 43 | 0.060 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2001 | 129 | 0.060 |
Why?
|
| Chlorhexidine | 1 | 2025 | 48 | 0.060 |
Why?
|
| Blood Glucose | 3 | 1999 | 1117 | 0.060 |
Why?
|
| Carrier State | 1 | 2025 | 80 | 0.060 |
Why?
|
| Nasal Cavity | 1 | 2025 | 56 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3829 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2025 | 180 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2017 | 463 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2833 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 5063 | 0.050 |
Why?
|
| Vomiting | 1 | 2023 | 103 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 84 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17753 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 859 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 209 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2023 | 208 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2022 | 49 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2021 | 79 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1490 | 0.040 |
Why?
|
| United States | 3 | 2023 | 12072 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 117 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2024 | 526 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 236 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 301 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2025 | 953 | 0.040 |
Why?
|
| Oocytes | 1 | 2021 | 283 | 0.040 |
Why?
|
| Insulin | 2 | 2001 | 1149 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 29 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 37 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 42 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2018 | 89 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 760 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 89 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 1999 | 253 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 523 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2025 | 6459 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2200 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1378 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1595 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8635 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5196 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1173 | 0.030 |
Why?
|
| Disease Management | 1 | 1998 | 558 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1680 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1722 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2022 | 2406 | 0.020 |
Why?
|
| Parenting | 1 | 1997 | 348 | 0.020 |
Why?
|
| Middle Aged | 1 | 2012 | 28601 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12936 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3360 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3711 | 0.020 |
Why?
|
| Emergency Service, Hospital | 2 | 2001 | 1224 | 0.010 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2001 | 170 | 0.010 |
Why?
|
| Office Visits | 1 | 1999 | 80 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 464 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2304 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1997 | 466 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 6196 | 0.000 |
Why?
|